Insys Therapeutics this week filed for Chapter 11 bankruptcy, just a few days after paying $225 million to settle a federal investigation that found the company bribed doctors to prescribe its leading drug Subsys, a fentanyl spray typically only used in cancer patients who are already taking other opioids. Subsys currently holds preferred status for 16% of covered lives, and is not covered for 25% of lives.

SOURCE: MMIT Analytics, as of 6/11/19